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Abstract
Background: Acquired periodic alternating nystagmus (PAN) is a rare but well-defined syndrome that consists of a
horizontal nystagmus that cyclically reverses its direction. PAN can be caused by degenerative, neoplastic, or toxic
diseases of the cerebellum and, in a few cases, by subacute cerebellar ataxia of immune origin.
Case presentation: A 44-year-old man came to our attention because of rapidly progressive gait instability and blurred
vision. Clinical examination showed PAN and a mild pancerebellar syndrome. Eye movement recordings disclosed a short
cycle PAN with significant slow-phase velocity only in darkness. Under the effect of a γ-aminobutyric acid type B (GABAB)
agonist, PAN was not modified. Right after treatment with intravenous immunoglobulin (IVIg) was started, PAN was
essentially eliminated. Three months after last dose of IVIg, this nystagmus reappeared.
Conclusions: IVIg resolved PAN in this patient. This finding may point to an autoimmune mechanism underlying this
patient’s nystagmus. This case suggests that the usefulness of IVIg at treating PAN might be worth a consideration in
similar clinical settings.
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Background
Acquired periodic alternating nystagmus (PAN) is a rare
but well-defined syndrome that consists of a horizontal
nystagmus that cyclically reverses its direction. The dur-
ation of cycles typically lasts 2 min [1], but shorter inter-
vals have been reported [2]. Several case reports indicate
that there might be a good response to GABAB-ergic
medications [3]. PAN has been reported in the context
of degenerative, neoplastic, or toxic diseases of the cere-
bellum and occasionally in subacute cerebellar ataxia of
presumed autoimmune origin [4].
Case presentation
A 44-year-old male patient with rapidly progressive gait
difficulties, blurred vision, and tremor of 6 months’ dur-
ation has been studied. His past medical history was
significant for human immunodeficiency virus (HIV) in-
fection and intravenous heroin use 14 years prior to
presentation. He also admitted that he occasionally
used cannabis and amphetamines, but they were used
prior to starting heroin. There was no history of head
trauma. He was on highly active antiretroviral therapy
(efavirenz, emtricitabine, and tenofovir) and metha-
done. Neurological examination revealed saccadic
smooth pursuit, abnormal eye movements suggestive
of PAN, dysarthria, head tremor as a “yes-yes” mo-
tion, and symmetric cerebellar tremor. There was
mild dysmetria on finger-nose testing on the left side
of the body. While resting or in action, he showed
non-rhythmic myoclonic jerks involving arm muscles.
Stance was broad-based without Romberg sign, and
gait was ataxic. Pinprick sensation and vibration sense
were mentioned as normal by the patient. Neither
pyramidal nor parkinsonian signs were present.
Videonystamographic recordings (Fig. 1A, B) showed
a short cycle PAN only apparent in the dark whose
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peak slow-phase velocity was approximately 6°/s in
light (Fig. 1A) and increased up to 30°/s in darkness
(Fig. 1B).
Brain magnetic resonance imaging (MRI) showed no
abnormalities, not even cerebellar atrophy. Comprehen-
sive serum and blood laboratory investigations were nor-
mal and included vitamin E levels, thyroid function,
antinuclear antibodies, and extensive serologies includ-
ing those of hepatitis C and B virus and syphilis (all
negative). He had a CD4+ count of 552 cells per cubic
millimeter. Cerebrospinal fluid (CSF) examination
showed lymphocytic predominant pleocytosis (37/μL),
high protein concentration (115 mg/dl, normal <40 mg/
dl), and absence of oligoclonal bands. Microbiological
CSF studies were negative; they included HIV (fully sup-
pressed HIV viral load with fewer than 20 copies/ml in
the CSF) and John Cunningham (JC) virus polymerase
chain reaction (PCR), the latter being negative in two
measurements. A whole-body [18F]6FDG positron emis-
sion tomography (PET) scan did not reveal an occult
neoplasm. Classic onconeuronal, anti-neuropil, and glu-
tamic acid decarboxylase (GAD Ab) 65 antibodies were
negative on serum and CSF measured with immunohis-
tochemistry as described in a recent practice guide [5].
At the same time, GAD Ab 65 was also measured on
sera with a commercial enzyme-linked immunosorbent
assay (ELISA) kit (ElisaRSR™ GADAb) and was not
detected.
The patient was started on clonazepam (at a dose of
1 mg every 8 h). Tremor slightly improved but PAN
remained unchanged (Fig. 1C.1). A trial with high-dose
IVIg (Flebogamma® produced by Grifols), at a dose of
17.5 g per day during 4 days for a weight of 70 kg, re-
sulted in a dramatic improvement of the abnormal eye
movements as PAN completely resolved (Fig. 1C.2).
During his hospital admission, the patient developed
biopsy proven cutaneous lymphocytic vasculitis, acute
severe autoimmune thrombocytopenia, and type IA dia-
betes. At this point, antibodies against gliadin and gan-
gliosides GM1, GM2, and GD1 were determined but
were not detected. Only after diabetes mellitus was diag-
nosed, levels of GAD Ab 65 in serum measured by
ELISA (ElisaRSR™ GADAb) were 81.70 U/mL (normal
<5 U/mL).
PAN disappeared readily after being started on IVIg.
Cerebellar ataxia and tremor improved gradually after
IVIg was administered monthly. Thrombocytopenia
responded to high-dose IVIg. However, diabetes went
unmodified under IVIg treatment. The patient was dis-
charged, with the intention to repeat the IVIg treatment
every 3 months at the dose described above. Right before
the next IVIg administration (two and a half months
after the previous one), the patient was only on clonaze-
pam, and oscillopsia was present with recordings show-
ing the reappearance of PAN with similar characteristics
(Fig. 1C.3). Treatment with monthly IVIg was then
scheduled, and the PAN disappeared again. After 1 year
of follow-up, the patient remains asymptomatic for
oscillopsia.
Discussion and conclusions
This case report represents the first short cycle PAN
successfully treated with IVIg after showing no response
to a GABAB agonist.
Fig. 1 Videonystagmographic recordings of a patient with periodic alternating nystagmus responsive to intravenous immunoglobulins. a
Horizontal slow-phase velocity (HSPV) recording at admission showed a maximum speed of 6.3°/s in light. b HSPV recording at admission exhib-
ited a maximum speed of 30.7°/s in the dark. c.1–c.3 Horizontal eye position (HEP) for each eye movement is plotted against time in the dark.
c.1 Under the effect of clonazepam alone showed PAN with a periodicity of 12 s comprised of 5 s of right-beating nystagmus and a 2-s steady
phase followed by 5 s of left-beating nystagmus. c.2 During the use of clonazepam and intravenous immunoglobulins, in which no nystagmus is
observed. c.3 During the use of clonazepam and 3 months after the last dose of intravenous immunoglobulins, PAN appeared again with similar
characteristics as in c.1
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A few decades ago, oculomotor disturbances were
found to account for the most prevalent sign of cerebel-
lar and brainstem dysfunction in a large series of HIV-
positive patients [6] and abnormal eye movements were
present in 93% of HIV-infected patients with neuro-
logical signs [7]. Various nystagmus including central
paroxysmal positional nystagmus [8] have been reported
in HIV-positive individuals, but no case of PAN associ-
ated with HIV has been described previously.
Cerebellar symptoms in HIV-infected patients are thus
frequent and might be the result of a direct effect of the
virus [9, 10], an opportunistic infection such as the ones
associated with JC virus [11, 12] and Cryptococcus [13],
or a degeneration in the setting of an immune restor-
ation disease related to the HIV infection [14]. No
robust case of an HIV-positive patient with an immune-
mediated cerebellar ataxia that responded to IVIg has
ever been reported.
In addition to the positive response of PAN to IVIg,
the development of other independent, autoimmune
processes during the patient’s hospital admission might
also suggest an autoimmune physiopathology for his
PAN. Only one prior publication has been found to as-
sociate PAN with a specific antibody [4]. In that case re-
port, the subject presented with progressive cerebellar
ataxia and PAN along with positivity to GAD Ab mea-
sured by immunohistochemistry. The authors suggested
that GAD Ab might have a pathogenic role, but PAN’s
response to IVIg was not evaluated.
In our patient, we believe that the presence of GAD
Ab measured by ELISA (ElisaRSR™ GADAb) was associ-
ated with the diagnosis of diabetes mellitus and not with
the cerebellar syndrome. At the time of diagnosis of the
cerebellar syndrome, GAD Ab measured by commercial
ELISA kit (ElisaRSR™ GADAb) and by immunohisto-
chemistry were both negative. Nowadays, immunohisto-
chemistry has become the gold standard for the
screening of onconeuronal, anti-neuropil and anti-GAD
antibodies relevant to neurological diseases [5]. Only
after diabetes mellitus appeared, GAD Ab measured by
the same commercial ELISA kit was detected. We
speculate that there may be another antibody yet to be
elucidated that might be involved in our patient’s PAN
and cerebellar ataxia.
It is well known that IVIg is successful in treating
autoimmune diseases presumably mediated by anti-
bodies, although its mechanism of action remains partly
unclear. At high doses, IVIg might harbor anti-
inflammatory effects.
To the best of our knowledge, there are isolated case
reports of PAN caused by inflammatory diseases such as
acute disseminated encephalomyelitis [15] and multiple
sclerosis [16]. High-dose corticosteroid made PAN grad-
ually disappear in light, but it persisted in darkness in
the patient with multiple sclerosis. In the case of the pa-
tient with acute disseminated encephalomyelitis, three
cycles of steroid pulse therapy and plasmapheresis
followed by oral administration of a steroid and tacroli-
mus in addition to several types of anticonvulsants failed
to resolve PAN. We propose that IVIg may have exerted
its effect on our patient’s PAN through anti-idiotypic
antibodies given that eminent anti-inflammatory medi-
cations such as steroids failed at treating PAN associated
with inflammatory neurological conditions.
The elimination of PAN was not coincidental since it
reappeared 3 months after the administration of the
IVIg, and there was no recurrence after IVIg was given
monthly. Therefore, this effect was reproducible and
suggests that it might be worth trying IVIg where the
clinical picture is suggestive of an autoimmune disorder.
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